Year None202420232022202120202019201820172016 Date Latest Press Release September 25, 2018 Eiger BioPharmaceuticals to Participate in Investor Conferences September 24, 2018 Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018 September 4, 2018 Eiger Announces Positive Meeting with FDA on Progeria Program August 27, 2018 Eiger BioPharmaceuticals to Participate in Investor Conferences August 13, 2018 Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia August 10, 2018 Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results August 7, 2018 Eiger BioPharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference August 6, 2018 Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health July 31, 2018 Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection June 4, 2018 Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™ Pagination First page « first Previous page ‹ previous … Page 12 Page 13 Page 14 Page 15 Current page 16 Page 17 Page 18 Page 19 Page 20 … Next page next › Last page last »